A magnetic immunochromatographic strip test for detection of human papillomavirus 16 E6.

Cervical cancer kills 230 000 women annually. Low-resource regions of the world are disproportionately burdened with 80% of the cases. Efficient screening methods are the key to decreasing the death toll from this disease. High-risk human papillomavirus (HPV) types have been identified as the etiological agent for >99% of cervical cancers. Infection with HPV is ubiquitous and is often resolved by the host. High-risk HPV infections leading to cervical cancer require the production of both HPV E6 and E7 oncoproteins (1)(2)(3)(4)(5). Thus, an assay capable of detecting high-risk HPV E6 from cervical swab samples may have a high positive predictive value and may help to accurately identify women at increased risk of progression to cancer. Internal studies have shown that cervical cancer cell lines produce ∼1 ng of E6 per 1 000 000 cells (data not shown). Work is continuing to quantify E6 amounts in cervical cell samples from clients with cancer, high-grade lesions (cervical intraepithelial neoplasia 2/3), and low-grade lesions (cervical intraepithelial neoplasia 1). Protein determinations performed on provider-collected cervical swabs indicate that the swabs collect 500 000 …

[1]  J. Struck,et al.  Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. , 2006, Clinical chemistry.

[2]  J. Rouleau,et al.  A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non‐ischaemic origin , 2005, European journal of heart failure.

[3]  M. Goh,et al.  Label-free monitoring of multiple biomolecular binding interactions in real-time with diffraction-based sensing , 2005 .

[4]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[5]  G. Hess,et al.  N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease. , 2005, Clinical laboratory.

[6]  Choongho Lee,et al.  Role of the PDZ Domain-Binding Motif of the Oncoprotein E6 in the Pathogenesis of Human Papillomavirus Type 31 , 2004, Journal of Virology.

[7]  M. Grace,et al.  Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.

[8]  K. Bhoola,et al.  Molecular genetics of human cervical cancer: role of papillomavirus and the apoptotic cascade , 2004, Biological chemistry.

[9]  Minh N. H. Nguyen,et al.  The PDZ Ligand Domain of the Human Papillomavirus Type 16 E6 Protein Is Required for E6's Induction of Epithelial Hyperplasia In Vivo , 2003, Journal of Virology.

[10]  J. Goh,et al.  A quantitative diffraction-based sandwich immunoassay. , 2003, Analytical biochemistry.

[11]  Lingling Wu,et al.  Endogenous Human Papillomavirus E6 and E7 Proteins Differentially Regulate Proliferation, Senescence, and Apoptosis in HeLa Cervical Carcinoma Cells , 2003, Journal of Virology.

[12]  P. Howley,et al.  Suppression of Cervical Cancer Cells E 6 / E 7 Promoter Is Required for Growth Repression of the Integrated Papillomavirus , 2000 .

[13]  M Fujita,et al.  Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Gustafson,et al.  Optical biosensor assay (OBA). , 1991, Clinical chemistry.

[15]  D. Lowy,et al.  HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. , 1989, The EMBO journal.

[16]  R. Schlegel,et al.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes , 1989, Journal of virology.